Baseline characteristics of patients and cord blood units
| Patients . | No. . |
|---|---|
| No. of patients | 27 |
| Median age, y (range) | 48 (19-67) |
| Male, percentage | 52 |
| Days to engraftment, n = 23 | |
| ANC more than 500 × 109/L, median (range) | 20 (13-35) |
| Platelet count more than 20 × 109/L, median (range) | 42 (25-162) |
| Pretransplantation CMV antibody titer, n = 25 (%) | |
| Positive | 16 (64) |
| Negative | 9 (36) |
| Cord blood units | |
| Total nucleated cell dose, ×107/kg, median (range) | |
| Donor 1 | 2.75 (1.87-67.00) |
| Donor 2 | 2.33 (1.81-3.94) |
| CD34+ cell dose, ×105/kg, median (range) | |
| Donor 1 | 7.20 (0.10-25.60) |
| Donor 2 | 3.80 (1.90-14.40) |
| Patients . | No. . |
|---|---|
| No. of patients | 27 |
| Median age, y (range) | 48 (19-67) |
| Male, percentage | 52 |
| Days to engraftment, n = 23 | |
| ANC more than 500 × 109/L, median (range) | 20 (13-35) |
| Platelet count more than 20 × 109/L, median (range) | 42 (25-162) |
| Pretransplantation CMV antibody titer, n = 25 (%) | |
| Positive | 16 (64) |
| Negative | 9 (36) |
| Cord blood units | |
| Total nucleated cell dose, ×107/kg, median (range) | |
| Donor 1 | 2.75 (1.87-67.00) |
| Donor 2 | 2.33 (1.81-3.94) |
| CD34+ cell dose, ×105/kg, median (range) | |
| Donor 1 | 7.20 (0.10-25.60) |
| Donor 2 | 3.80 (1.90-14.40) |